Literature DB >> 19466750

Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

Jennifer Saussede-Aim1, Eva-Laure Matera, Cristiano Ferlini, Charles Dumontet.   

Abstract

Microtubules are involved in a variety of essential cell functions. Their role during mitosis has made them a target for anti-cancer drugs. However development of resistance has limited their use. It has been established that enhanced beta3-tubulin expression is correlated with reduced response to antimicrotubule agent-based chemotherapy or worse outcome in a variety of tumor settings. However little is known regarding the regulation of beta3-tubulin expression. We investigated the regulatory mechanisms of expression of beta3-tubulin in the MCF-7 cell line, a model of hormone-dependent breast cancer. Exposure of MCF-7 cells to estradiol was found to induce beta3-tubulin mRNA as well as beta3-tubulin protein expression. Conversely, we did not observe induction of beta3-tubulin mRNA by estradiol in MDA-MB-231 cells which are negative for the estrogen receptor (ER). In order to determine whether beta3-tubulin up-regulation is mediated through the ER pathway, MCF-7 cells were exposed to two ER modulators. Exposure to tamoxifen, a selective estrogen receptor modulator, completely abolished the beta3-tubulin mRNA induction due to estradiol in MCF-7 cells. This result was confirmed with fulvestrant, a pure antagonist of ER. These results demonstrate that the effect of estradiol on beta3-tubulin transcription is mediated through an ER dependent pathway. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466750     DOI: 10.1002/cm.20377

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  6 in total

1.  Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements.

Authors:  Ryenne N Ogburn; Lorrain Jin; He Meng; Michael C Fitzgerald
Journal:  J Proteome Res       Date:  2017-10-11       Impact factor: 4.466

2.  Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.

Authors:  Aaron R Tipton; Geoffrey O Nyabuto; Jill A Trendel; Travis M Mazur; John P Wilson; Suzan Wadi; Jacob S Justinger; Garret L Moore; Peter T Nguyen; Deborah J Vestal
Journal:  Biochem Biophys Res Commun       Date:  2016-08-31       Impact factor: 3.575

3.  Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Authors:  Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee
Journal:  Invest New Drugs       Date:  2015-12-21       Impact factor: 3.850

Review 4.  βIII-Tubulin Gene Regulation in Health and Disease.

Authors:  Alastair M P Duly; Felicity C L Kao; Wee Siang Teo; Maria Kavallaris
Journal:  Front Cell Dev Biol       Date:  2022-04-28

5.  Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.

Authors:  Marta De Donato; Mara Fanelli; Marisa Mariani; Giuseppina Raspaglio; Deep Pandya; Shiquan He; Paul Fiedler; Marco Petrillo; Giovanni Scambia; Cristiano Ferlini
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

6.  Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

Authors:  S Terry; G Ploussard; Y Allory; N Nicolaiew; F Boissière-Michot; P Maillé; L Kheuang; E Coppolani; A Ali; F Bibeau; S Culine; R Buttyan; A de la Taille; F Vacherot
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.